Your browser doesn't support javascript.
loading
Body mass index may predict the response to ipilimumab in metastatic melanoma: An observational multi-centre study.
Richtig, Georg; Hoeller, Christoph; Wolf, Martin; Wolf, Ingrid; Rainer, Barbara M; Schulter, Günter; Richtig, Markus; Grübler, Martin R; Gappmayer, Anna; Haidn, Thomas; Kofler, Julian; Huegel, Rainer; Lange-Asschenfeldt, Bernhard; Pichler, Martin; Pilz, Stefan; Heinemann, Akos; Richtig, Erika.
Afiliación
  • Richtig G; Otto Loewi Research Center, Pharmacology Section, Medical University of Graz, Graz, Austria.
  • Hoeller C; Department of Dermatology, Medical University of Graz, Graz, Austria.
  • Wolf M; Department of Dermatology, Medical University of Vienna, Vienna, Austria.
  • Wolf I; Department of Dermatology, Medical University of Graz, Graz, Austria.
  • Rainer BM; Department of Dermatology, State Hospital Wiener Neustadt, Wiener Neustadt, Austria.
  • Schulter G; Department of Dermatology, Medical University of Graz, Graz, Austria.
  • Richtig M; Department of Dermatology, Medical University of Graz, Graz, Austria.
  • Grübler MR; Department of Psychology, Biological Psychology Unit, University of Graz, Graz, Austria.
  • Gappmayer A; Department of Dermatology, Medical University of Graz, Graz, Austria.
  • Haidn T; Swiss Cardiovascular Center Bern, Department of Cardiology, Bern University Hospital, Bern, Switzerland.
  • Kofler J; Department of Internal Medicine, Division of Endocrinology and Diabetology, Medical University of Graz, Graz, Austria.
  • Huegel R; Department of Dermatology, State Hospital Wiener Neustadt, Wiener Neustadt, Austria.
  • Lange-Asschenfeldt B; Department of Dermatology, State Hospital Wiener Neustadt, Wiener Neustadt, Austria.
  • Pichler M; Department of Dermatology and Venereology, State Hospital Klagenfurt, Klagenfurt am Wörthersee, Austria.
  • Pilz S; Department of Dermatology and Venereology, State Hospital Klagenfurt, Klagenfurt am Wörthersee, Austria.
  • Heinemann A; Department of Dermatology and Venereology, State Hospital Klagenfurt, Klagenfurt am Wörthersee, Austria.
  • Richtig E; Skin Cancer Center Charité, Department of Dermatology and Allergy, Charité-Universitätsmedizin Berlin, Berlin, Germany.
PLoS One ; 13(10): e0204729, 2018.
Article en En | MEDLINE | ID: mdl-30273398
INTRODUCTION: Immunotherapy is a well-established treatment option in patients with metastatic melanoma. However, biomarkers that can be used to predict a response in these patients have not yet been found, putting patients at risk of severe side effects. METHODS: In this retrospective analysis, we investigated the association between the body mass index and ipilimumab treatment response in patients with metastatic melanoma. Patients with metastatic melanoma who received a monotherapy of up to 4 doses of ipilimumab (3 mg/kg) every 3 weeks from 2011 to 2014 in three major hospitals in Austria were included. Patients were classified into two groups: normal group (BMI<25) and overweight group (BMI≥25). RESULTS: 40 patients had a normal BMI, and 36 had a BMI above normal. Patients with a BMI that was above normal showed significantly higher response rates (p = 0.024, χ2), and lower likelihood of brain metastases (p = 0.012, χ2). No differences were found between both groups with respect to gender (p = 0.324, χ2), T-stage (p = 0.197, χ2), or the occurrence of side effects (p = 0.646, χ2). Patients with a BMI above normal showed a trend towards longer overall survival (p = 0.056, Log-Rank), but no difference was found regarding progression-free survival (p = 0.924, Log-Rank). CONCLUSIONS: The BMI correlated with the response to ipilimumab treatment in a cohort of metastatic melanoma patients.
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Ipilimumab / Antineoplásicos Inmunológicos / Melanoma Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Female / Humans / Male País/Región como asunto: Europa Idioma: En Revista: PLoS One Asunto de la revista: CIENCIA / MEDICINA Año: 2018 Tipo del documento: Article País de afiliación: Austria Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Ipilimumab / Antineoplásicos Inmunológicos / Melanoma Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Female / Humans / Male País/Región como asunto: Europa Idioma: En Revista: PLoS One Asunto de la revista: CIENCIA / MEDICINA Año: 2018 Tipo del documento: Article País de afiliación: Austria Pais de publicación: Estados Unidos